A5038633732- Herpesvirus Infections and Treatments
- Cytomegalovirus and herpesvirus research
- Poxvirus research and outbreaks
- Virus-based gene therapy research
- Animal Virus Infections Studies
- Toxin Mechanisms and Immunotoxins
- Vector-borne infectious diseases
- Parvovirus B19 Infection Studies
- Virology and Viral Diseases
- Bartonella species infections research
- Immune Cell Function and Interaction
- Respiratory viral infections research
- Viral-associated cancers and disorders
- Dermatology and Skin Diseases
- interferon and immune responses
- T-cell and Retrovirus Studies
- SARS-CoV-2 and COVID-19 Research
- Systemic Lupus Erythematosus Research
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses
- Toxoplasma gondii Research Studies
- Influenza Virus Research Studies
- Vaccine Coverage and Hesitancy
- Immune Response and Inflammation
- Hepatitis Viruses Studies and Epidemiology
Stanford University
2015-2025
VIR Biotechnology (United States)
2020-2025
Vir Biotechnology (Switzerland)
2025
Chinese Center For Disease Control and Prevention
2016-2020
Stanford Medicine
1983-2017
Lucile Packard Children's Hospital
1983-2017
Hasheminejad Kidney Center
2017
Iran University of Medical Sciences
2017
Pediatrics and Genetics
2006-2008
Bipar
2007
Objective. The objective of this investigation was to establish the safety high-dose (HD) acyclovir for treatment neonatal herpes simplex virus (HSV) disease. In addition, an estimate therapeutic efficacy sought, both with respect mortality and morbidity. Virologic HD also assessed. Participants. Infants who were ≤28 days old whose disease considered be caused by HSV enrolled in study. Patients central nervous system (CNS; N = 28) or disseminated (N 41) infection offered participation trial....
Antibody-dependent enhancement (ADE) of disease is a general concern for the development vaccines and antibody therapies because mechanisms that underlie protection against any virus have theoretical potential to amplify infection or trigger harmful immunopathology. This possibility requires careful consideration at this critical point in pandemic coronavirus 2019 (COVID-19), which caused by severe acute respiratory syndrome 2 (SARS-CoV-2). Here we review observations relevant risks ADE...
Objective. During the 2 decades in which effective antiviral therapies have been available for neonatal herpes simplex virus (HSV) disease, changes documented not only outcomes of infected infants, but also natural history disease itself. Numerous studies previously reported that early institution therapy is beneficial to outcome disease. The objective this study was provide an update HSV identify means by future improvements management HSV-infected neonates can be made. Design/Methods....
The controlled evaluation of vidarabine as therapy neonatal herpes simplex virus (HSV) infection provided an opportunity to collect data further assess the natural history maternal and newborn infections. Women delivering infected babies were young, nulliparous, infrequent aborters. Nearly 50% gestations ended in premature labor. Maternal was asymptomatic 39 56 (70%) mothers, at time delivery. However, risk factors included a past genital any exposure sexual partner with presumed HSV...
We investigated the consequences of maternal infection with varicella-zoster virus in a prospective study 43 pregnancies complicated by varicella and 14 herpes zoster. Nine pregnant women had associated morbidity--pneumonia (4 women), death (1), premature labor 42), delivery (2 zoster (1). Intrauterine was identified on basis clinical evidence (anomalies characteristic congenital syndrome, acute at birth, or infancy) immunologic (IgM antibody to neonatal period, persistent IgG one two years...
In a controlled trial comparing acyclovir with vidarabine in the treatment of neonatal herpes simplex virus (HSV) infection, we found no significant difference between treatments adjusted mortality and morbidity. Hence, sought to define for entire cohort (n = 202) clinical characteristics that best predicted eventual outcome these neonates.
Despite the use of vidarabine, herpes simplex virus (HSV) infection in neonates continues to be a disease high morbidity and mortality. We undertook controlled trial comparing vidarabine with acyclovir for treatment neonatal HSV infection.
We studied the risk of herpes simplex virus (HSV) infections in neonates exposed to HSV at time vaginal delivery mothers with a history recurrent genital infections. None 34 infants type 2 acquired an infection. On basis this sample, 95 percent confidence limit for theoretical maximum infection rate is 8 percent. Cord blood or obtained during first two weeks life was available from 33 exposed, uninfected neonates. All samples possessed demonstrable neutralizing antibody 2, and 79 had titers...
We compared the clinical presentation of 95 newborns with herpes simplex virus (HSV) infection from 1973 through 1981 (first period) data 196 evaluated 1982 1987(second period). There was a significant change in these infants. From first to second period, frequency disseminated disease decreased 50.5% 22.9%, whereas skin, eye, and mouth (SEM) diseases increased 17.9% 43.4% (P < .001). The infants central nervous system (CNS) remained relatively unchanged - 31.6% versus 33.7%. also...
The patterns of cellular immune responses induced by live attenuated influenza vaccine (LAIV) versus those the trivalent inactivated (TIV) have not been studied extensively, especially in children. goals this study were to evaluate effects TIV and LAIV immunization on immunity A virus children adults explore factors associated with variations vaccines among individuals. gamma interferon (IFN-gamma) flow cytometry assay was used measure IFN-gamma-producing (IFN-gamma+) NK T cells peripheral...
Chickenpox, the primary infection caused by varicella-zoster virus, affects more than 3 million children a year in United States. Although usually self-limited, chickenpox can cause prolonged discomfort and is associated with infrequent but serious complications.To evaluate effectiveness of acyclovir for treatment chickenpox, we conducted multicenter, double-blind, placebo-controlled study involving 815 healthy 2 to 12 years old who contracted chickenpox. Treatment was begun within first 24...
The reactivation of varicella–zoster virus from latency causes zoster and is common among recipients hematopoietic-cell transplants.
To investigate the cell tropism and pathogenicity of varicella-zoster virus (VZV) strains, we analyzed VZV replication by using SCID-hu mice that carry human fetal thymus/liver implants under kidney capsule or as subcutaneous skin implants. MRC-5 cells infected with wild-type Oka strain, used in live attenuated varicella vaccine, were injected into The surgically removed 2, 7, 14, 21 days postinfection. titer from peaked on day 7 for strain 14 strain. Histological analysis showed necrotic...
Cerebrospinal fluid (CSF) specimens from 77 neonates with herpes simplex virus (HSV) disease were evaluated retrospectively by polymerase chain reaction (PCR). Samples collected 202 infants enrolled in a National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group trial that compared vidarabine acyclovir for the treatment neonatal HSV infection. DNA was detected CSF 26 (76%) 34 CNS disease, 13 (93%) 14 disseminated infection, 7 (24%) 29 skin, eye, or mouth (SEM)...
Currently two vaccines, trivalent inactivated influenza vaccine (TIV) and live attenuated (LAIV), are licensed in the USA. Despite previous studies on immune responses induced by these a comparative study of influence prior vaccination serum antibody B-cell to new LAIV or TIV has not been reported. During 2005/6 season, we quantified adults with differing histories year: LAIV, TIV, neither. Blood samples were collected days 0, 7-9 21-35 after immunization used for HAI assay assays. Total...
ABSTRACT The SCID-hu mouse implanted with human fetal tissue is a novel model for investigating viral pathogenesis. Infection of skin implants was used to investigate the basis clinical attenuation varicella-zoster virus (VZV) strain, V-Oka, from which newly licensed vaccine made. pathogenicity V-Oka compared that its parent, P-Oka, another low-passage isolate, strain Schenke (VZV-S), and VZV-Ellen, standard laboratory strain. role glycoprotein C (gC) in infectivity assessed by using...